Literature DB >> 28063616

Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis.

Clara Matute-Blanch1, Jordi Río2, Luisa M Villar3, Luciana Midaglia2, Sunny Malhotra2, José C Álvarez-Cermeño3, Angela Vidal-Jordana2, Xavier Montalban2, Manuel Comabella4.   

Abstract

Chitinase 3-like 1 (CHI3L1) plays a prognostic role in patients with multiple sclerosis (MS). Here, we investigated a potential association between CHI3L1 and the response to interferon-beta (IFNβ) and glatiramer acetate (GA). Serum CHI3L1 levels were measured by ELISA in 117 relapsing-remitting MS (RRMS) patients, 76 IFNβ-treated and 41 GA-treated patients. CHI3L1 levels were increased by GA (p=0.014) but unchanged by IFNβ (p=0.830). CHI3L1 was associated with IFNβ response and levels were higher in non-responder group (p=0.020), while GA showed no responder effect (p=0.943). These results suggest a role for CHI3L1 as response biomarker to IFNβ in RRMS patients.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarkers; Chitinase 3-like 1; Glatiramer acetate; Interferon-beta; Multiple sclerosis

Mesh：

Substances：

Year:  2016        PMID： 28063616     DOI： 10.1016/j.jneuroim.2016.12.006

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


  10 in total

Review 1.  Update on Multiple Sclerosis Molecular Biomarkers to Monitor Treatment Effects.

Authors:  Viviana Nociti; Marina Romozzi; Massimiliano Mirabella
Journal:  J Pers Med       Date:  2022-03-31

Review 2.  Current and Future Biomarkers in Multiple Sclerosis.

Authors:  Jennifer Yang; Maysa Hamade; Qi Wu; Qin Wang; Robert Axtell; Shailendra Giri; Yang Mao-Draayer
Journal:  Int J Mol Sci       Date:  2022-05-24       Impact factor: 6.208

3.  Role of Chitinase-3-like Protein 1 in Cardioprotection and Angiogenesis by Post-Infarction Exercise Training.

Authors:  Zhuo Li; Fangnan Wu; Lei Xi; Zhenjun Tian
Journal:  Biomedicines       Date:  2022-04-29

4.  CSF chitinase 3-like-1 association with disability of primary progressive MS.

Authors:  Francisco Pérez-Miralles; Daniel Prefasi; Antonio García-Merino; Francisco Gascón-Giménez; Nicolás Medrano; Jessica Castillo-Villalba; Laura Cubas; Carmen Alcalá; Sara Gil-Perotín; Rocío Gómez-Ballesteros; Jorge Maurino; Esther Álvarez-García; Bonaventura Casanova
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-07-01

5.  Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis.

Authors:  Sara Gil-Perotin; Jessica Castillo-Villalba; Laura Cubas-Nuñez; Raquel Gasque; David Hervas; Josep Gomez-Mateu; Carmen Alcala; Francisco Perez-Miralles; Francisco Gascon; Jose Andres Dominguez; Bonaventura Casanova
Journal:  Front Neurol       Date:  2019-09-23       Impact factor: 4.003

Review 6.  Molecular biomarkers in multiple sclerosis.

Authors:  Tjalf Ziemssen; Katja Akgün; Wolfgang Brück
Journal:  J Neuroinflammation       Date:  2019-12-23       Impact factor: 8.322

Review 7.  The Role of Cytotoxic T-Lymphocyte Antigen 4 in the Pathogenesis of Multiple Sclerosis.

Authors:  Maria Sofia Basile; Placido Bramanti; Emanuela Mazzon
Journal:  Genes (Basel)       Date:  2022-07-24       Impact factor: 4.141

8.  Neurofilament light chain predicts disease activity in relapsing-remitting MS.

Authors:  Kristin N Varhaug; Christian Barro; Kjetil Bjørnevik; Kjell-Morten Myhr; Øivind Torkildsen; Stig Wergeland; Laurence A Bindoff; Jens Kuhle; Christian Vedeler
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-11-28

9.  Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis: A Randomized, Controlled Trial.

Authors:  Helene Højsgaard Chow; Jacob Talbot; Henrik Lundell; Camilla Gøbel Madsen; Lisbet Marstrand; Theis Lange; Mie Reith Mahler; Sophie Buhelt; Rikke Holm Hansen; Morten Blinkenberg; Jeppe Romme Christensen; Per Soelberg Sørensen; Marina Rode von Essen; Hartwig Roman Siebner; Finn Sellebjerg
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-08-24

Review 10.  Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations.

Authors:  Tamás Biernacki; Zsófia Kokas; Dániel Sandi; Judit Füvesi; Zsanett Fricska-Nagy; Péter Faragó; Tamás Zsigmond Kincses; Péter Klivényi; Krisztina Bencsik; László Vécsei
Journal:  Int J Mol Sci       Date:  2022-03-21       Impact factor: 5.923
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.